SCHEMBL6360388

SCHEMBL6360388

CNC(=O)NS(=O)(=O)c1cc(CCNC(=O)c2cc(C(C)(C)C)ccc2OC)ccc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC9 O60706 2/20 0.56
ABCC8 Q09428 2/20 0.56
KCNJ11 Q14654 2/20 0.56
LMNA P02545 3/20 0.53
MAPT P10636 2/20 0.53
ALDH1A1 P00352 2/20 0.49
NLRP3 Q96P20 4/20 0.48
MEN1 O00255 1/20 0.45
ABCC3 O15438 1/20 0.45
ABCC4 O15439 1/20 0.45
ABCB11 O95342 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CFTR P13569 1/20 0.45
TSHR P16473 1/20 0.45
HTR2A P28223 1/20 0.45
CYP2C19 P33261 1/20 0.45
PPARG P37231 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL726540 0.94 ABCC9 (0.64) ABCC9ABCC8KCNJ11LMNAMAPT
SCHEMBL6363889 0.91 ABCC9 (0.69) ABCC9ABCC8KCNJ11LMNAMAPT
SCHEMBL6360950 0.90 ABCC9 (0.56) ABCC9ABCC8KCNJ11LMNAMAPT
SCHEMBL6364342 0.90 ABCC9 (0.58) ABCC9ABCC8KCNJ11LMNAMAPT
SCHEMBL6360800 0.90 ABCC9 (0.56) ABCC9ABCC8KCNJ11LMNAMAPT
SCHEMBL6364630 0.89 ABCC9 (0.57) ABCC9ABCC8KCNJ11LMNAMAPT
SCHEMBL6360174 0.89 ABCC9 (0.56) ABCC9ABCC8KCNJ11LMNAMAPT
SCHEMBL6362944 0.89 ABCC9 (0.56) ABCC9ABCC8KCNJ11LMNAMAPT
SCHEMBL6361601 0.89 ABCC9 (0.54) ABCC9ABCC8KCNJ11LMNAMAPT
SCHEMBL6357537 0.89 ABCC9 (0.54) ABCC9ABCC8KCNJ11LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1117409-B1 BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-BLOCKERS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AVENTIS PHARMA GMBH (DE) 2005-01-26 EP disclosed
US-6414030-B1 1-((5-(2-(5-TERT-BUTYL-2-METHOXYBENZAMIDO)ETHYL)-2-METHOXYPHEN YL)-SULFONYL)-3-METHYLTHIOUREA AND PROPANOLOL FOR EXAMPLE AVENTIS PHARMA DEUTSCHLAND, GMBH (DE) 2002-07-02 US disclosed
US-20020082300-A1 USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-06-27 US disclosed
EP-1117409-A2 USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM Aventis Pharma Deutschland GmbH (DE) 2001-07-25 EP disclosed
WO-2000015204-A2 USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082300-A1 USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS UTS2R, TST, SIGMAR1 ABCC9 340/4885ABCC8 196/4885KCNJ11 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.